Factors associated with elevated pulmonary vascular resistance in ambulatory patients with end-stage heart failure accepted for heart transplant

被引:6
|
作者
Szczurek, Wioletta [1 ]
Gasior, Mariusz [2 ]
Skrzypek, Michal [3 ]
Romuk, Ewa [4 ]
Szygula-Jurkiewicz, Bozena [2 ]
机构
[1] Silesian Ctr Heart Dis Zabrze, Ul Sklodowskiej Curie 9, PL-41800 Zabrze, Poland
[2] Med Univ Silesia, Sch Med Sci Zabrze, Dept Cardiol 3, Katowice, Poland
[3] Med Univ Silesia, Sch Publ Hlth Bytom, Dept Biostat, Katowice, Poland
[4] Med Univ Silesia, Sch Med Sci Zabrze, Dept Biochem, Katowice, Poland
来源
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ | 2020年 / 130卷 / 10期
关键词
factor; heart failure; pulmonary hypertension; pulmonary vascular resistance; LIVER DYSFUNCTION; MELD-XI; INTERNATIONAL SOCIETY; ALKALINE-PHOSPHATASE; PROGNOSTIC VALUE; HYPERTENSION; OUTCOMES; DISEASE; MODEL;
D O I
10.20452/pamw.15532
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
INTRODUCTION Pulmonary hypertension (PH) is a common complication of heart failure (HF) that results in worse prognosis and heart complications following heart transplantation. To better define and understand left-sided PH, it is necessary to integrate the clinical context, noninvasive assessment, and invasive hemodynamic variables. OBJECTIVES The aim of the study was to search for noninvasive factors related to the presence of PH with elevated pulmonary vascular resistance (PVR) in patients with advanced HF. PATIENTS AND METHODS The study is a retrospective analysis of 282 patients with end-stage HF accepted for transplantation in the cardiology department between 2016 and 2018. A panel of laboratory tests, echocardiography, ergospirometry, and right heart catheterization were performed in all included patients. The Model for End-Stage Liver Disease Excluding INR (MELD-XI) and the Heart Failure Survival Score (HFSS) were calculated according to the appropriate formulas. RESULTS The median age was 57 (51-60) years and 87.6% of patients were men. Pulmonary hypertension with elevated PVR was found in 30.1% of patients. The multivariable logistic regression analysis confirmed that lower HFSS (OR, 0.59; 95% CI, 0.383-0.908; P = 0.016), and higher MELD-XI scores (OR, 1.13; 95% CI, 1.024-1.24; P = 0.014), as well as higher alkaline phosphatase levels (OR, 1.02; 95% CI, 1.007-1.024; P <0.001) were independent factors associated with increased PVR. CONCLUSIONS To the best of our knowledge, this is the first study to demonstrate that high MELD-XI and low HFFS scores, as well as high alkaline phosphatase serum concentrations were independently associated with increased PVR in patients with advanced HF referred for transplantation.
引用
收藏
页码:830 / 836
页数:7
相关论文
共 50 条
  • [21] End-of-Life Care for End-stage Heart Failure Patients
    Lee, Ju-Hee
    Hwang, Kyung-Kuk
    KOREAN CIRCULATION JOURNAL, 2022, 52 (09) : 659 - 679
  • [22] Modified Model for End-Stage Liver Disease Is an Indicator of the Ineffectiveness of Sildenafil Treatment in Patients With Advanced Heart Failure and Increased Pulmonary Vascular Resistance
    Szczurek, Wioletta
    Gasior, Mariusz
    Skrzypek, Michal
    Kaczmarski, Jacek
    Szygula-Jurkiewicz, Bozena
    TRANSPLANTATION PROCEEDINGS, 2020, 52 (08) : 2440 - 2446
  • [23] Intergenerational Caregivers of Parents With End-Stage Heart Failure
    Alonso, Windy Williams
    Kitko, Lisa A.
    Hupcey, Judith E.
    RESEARCH AND THEORY FOR NURSING PRACTICE, 2018, 32 (04) : 413 - 435
  • [24] Resistance Training Improves Vasoreactivity in End-Stage Heart Failure Patients on Inotropic Support
    Dean, Abigail S.
    Libonati, Joseph R.
    Madonna, Deborah
    Ratcliffe, Sarah J.
    Margulies, Kenneth B.
    JOURNAL OF CARDIOVASCULAR NURSING, 2011, 26 (03) : 218 - 223
  • [25] Surgical Therapy of End-Stage Heart Failure in Pediatric Patients
    Ayik, F.
    Oguz, E.
    Engin, C.
    Yagdi, T.
    Ulger, Z.
    Atay, Y.
    Ozbaran, M.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (03) : 935 - 937
  • [26] When the Heart Runs Out of Heartbeats Treatment Options for Refractory End-Stage Heart Failure
    Ahmad, Tariq
    Patel, Chetan B.
    Milano, Carmelo A.
    Rogers, Joseph G.
    CIRCULATION, 2012, 125 (23) : 2948 - 2955
  • [27] MitraClip® therapy in patients with end-stage systolic heart failure
    Franzen, Olaf
    van der Heyden, Jan
    Baldus, Stephan
    Schlueter, Michael
    Schillinger, Wolfgang
    Butter, Christian
    Hoffmann, Rainer
    Corti, Roberto
    Pedrazzini, Giovanni
    Swaans, Martin J.
    Neuss, Michael
    Rudolph, Volker
    Suerder, Daniel
    Gruenenfelder, Juerg
    Eulenburg, Christine
    Reichenspurner, Hermann
    Meinertz, Thomas
    Auricchio, Angelo
    EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (05) : 569 - 576
  • [28] End-Stage Heart Failure in Cardiac Sarcoidosis
    Velikanova, Diana
    Poyhonen, Pauli
    Lehtonen, Jukka
    Simonen, Piia
    Uusitalo, Valtteri
    Vihinen, Tapani
    Kaikkonen, Kari
    Haataja, Petri
    Kerola, Tuomas
    Rissanen, Tuomas T.
    Vepsalainen, Ville
    Alatalo, Aleksi
    Pietila-Effati, Paivi
    Kupari, Markku
    CIRCULATION, 2024, 149 (11) : 885 - 887
  • [29] Surgical management of end-stage heart failure
    Sharkey, A.
    Warriner, D.
    Braidley, P.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2012, 73 (11) : 633 - 639
  • [30] Frailty in the End-Stage Lung Disease or Heart Failure Patient: Implications for the Perioperative Transplant Clinician
    Bottiger, Brandi A.
    Nicoara, Alina
    Snyder, Laurie D.
    Wischmeyer, Paul E.
    Schroder, Jacob N.
    Patel, Chetan B.
    Daneshmand, Mani A.
    Sladen, Robert N.
    Ghadimi, Kamrouz
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2019, 33 (05) : 1382 - 1392